Navigation Links
OTC Markets Group Congratulates Organovo Holdings on Move to NYSE MKT
Date:7/11/2013

NEW YORK, July 11, 2013 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM) congratulates Organovo Holdings Inc. on its listing on the New York Stock Exchange's NYSE MKT.

(Logo: http://photos.prnewswire.com/prnh/20110118/MM31963LOGO )

In October 2012, Organovo, a biotechnology company focused on delivering breakthrough three-dimensional (3D) bioprinting technology, qualified for trading on OTCQX®, the best marketplace with qualified companies.  In that time, the company's stock price has more than doubled to $5.40 and its market capitalization is now $318 million.  Since joining OTCQX, Organovo's management team has increased shareholder value and achieved liquidity of over 120 million shares traded, representing approximately $478 million of dollar volume. 

"Organovo's rapid growth has allowed them to smoothly graduate from OTCQX to NYSE MKT.  We congratulate them on this important milestone and are proud to have helped contribute to their success as a public company," said R. Cromwell Coulson, President and CEO of OTC Markets Group.  "OTCQX is a springboard and proving ground for high-quality U.S. and global growth companies to execute their business plans and grow into a national stock exchange listing.  In the past five years, over 300 companies have moved from our marketplaces to the NYSE and NASDAQ.  We look forward to nurturing more companies like Organovo as they enter the public market and provide a robust and transparent platform for high quality trading of their shares."

"OTCQX helped us expand our investor base and increase our average daily trading volume, which was instrumental in enabling us to qualify for an NYSE MKT listing," said Keith Murphy, Chairman and CEO of Organovo Holdings.  "We recognize the impact OTCQX has had on our success and appreciate the support OTC Markets Group has provided to ensure that success."

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities. Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. We organize these securities into marketplaces to better inform investors of opportunities and risks – OTCQX®, The Best Marketplace with Qualified Companies; OTCQB®, The Venture Stage Marketplace with U.S. Reporting Companies; and OTC Pink®, The Open Marketplace with Variable Reporting Companies. Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors. To learn more about how we create better informed and more efficient financial marketplaces, visit www.otcmarkets.com.

OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.

Subscribe to the OTC Markets RSS Feed


'/>"/>
SOURCE OTC Markets Group Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
5. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
6. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
7. Animal Biotechnology - Technologies, Markets and Companies
8. Gene Therapy - Technologies, Markets and Companies
9. Biomarkers - Technologies, Markets and Companies
10. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
11. MarketsandMarkets: Chronic Lymphocytic Leukemia Therapeutics Market Worth $2.2 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
(Date:10/9/2017)... ... ... At its national board meeting in North Carolina, ARCS® Foundation President ... and Astronomy, has been selected for membership in ARCS Alumni Hall of Fame ... Prize in Fundamental physics for the discovery of the accelerating expansion of the universe, ...
(Date:10/9/2017)... , ... October 09, 2017 ... ... on October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® ... gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially ... cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their own facilities, ...
Breaking Biology Technology:
(Date:5/16/2017)...  Veratad Technologies, LLC ( www.veratad.com ), an innovative ... verification solutions, announced today they will participate as a ... thru May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions ... evolving digital world, defining identity is critical to nearly ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert ... a media edge server, the M820, which features the company,s hybrid ... software provided by Tera Probe, Inc., will be showcased during the ... the NAB show at the Las Vegas ... ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 30.37% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
Breaking Biology News(10 mins):